Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 6, 1998

View Archived Issues

SkyePharma will acquire DepoTech

Chinese researchers synthesize cytotoxic alkaloid derivative HH-07A

AltaRex moves to conduct clinical trial with OvaRex in more advanced ovarian cancer

Siga, U.S. Army collaborate on development of staphylococcal vaccine

Merck finally reveals chemical structure of lead COX-2 inhibitor

Novel endothelin antagonists claimed for cardiovascular, cerebrovascular and other disorders

New antifungal and antitumor antibiotic produced by Saccharothrix

SB discloses isoquinolyl-benzamide anticonvulsants

FR-110302 as clinical candidate for asthma, atherosclerosis and other inflammatory disorders

Phase II trial supports efficacy of pentapeptide antidepressant

YM-75466 possesses significant advantages over warfarin as oral anticoagulant

Favorable efficacy, side effect profile seen with belaperidone in preclinical and clinical studies

KW-8232 prevents bone loss and inhibits bone resorption in animal model of osteopenia

Rotavirus vaccine now on the market in U.S.

Selective agonist activity of Bayer's Bay-x-3702 at 5-HT1A receptors confirmed in vivo

Single- and multiple-dose safety, PK studies conducted with M-100907 in healthy volunteers

Phase II trials demonstrate ability of Onco TCS to reduce tumor size in NHL patients

GABA-B antagonist from Novartis with potential in epilepsy-associated memory disturbances

CPMP votes against approval recommendation for propentofylline

Progen commences phase I trials of PI-88 in the U.K.

Neurogen and Pfizer extend and expand CNS collaboration

Procept and Pacific Pharmaceuticals sign letter of intent regarding potential merger

SIB-1508Y demonstrates neuroprotective effects in rat model of PD

Gliatech's first drug candidate begins phase I clinical trials

FDA approves Actiq for treatment of breakthrough cancer pain

Novel, noninvasive procedure cleared by FDA for debilitating sleep and breathing disorder

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...